Recent Updates — ETRA

Electra Therapeutics, Inc. closed its initial public offering on September 21, 2026, selling 23,333,334 shares of common stock at a price of $15.00 per share. The transaction generated approximately $350.0 million in aggregate gross proceeds before deducting underwriting discounts and estimated offering expenses. Concurrently with the IPO closing, the company filed an amended and restated certificate of incorporation and adopted amended and restated bylaws with the State of Delaware. Electra Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases.